Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acetic acid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Acetic acid. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-003481-28 Sponsor Protocol Number: RRK5108 Start Date*: 2017-12-21
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: A pilot randomised controlled trial to examine the efficacy and optimal dose of Acetic Acid to treat colonised burns wounds.
    Medical condition: Colonised burn wounds
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10053615 Thermal burn PT
    20.0 10021881 - Infections and infestations 10051548 Burn infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-002807-33 Sponsor Protocol Number: NLA-C003P Start Date*: 2004-11-09
    Sponsor Name:Biolipox AB
    Full Title: A double blind, randomized, cross-over, placebo controlled study, evaluating the time-to-onset of action of BLX000441-002 nasal spray in healthy volunteers.
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004844-23 Sponsor Protocol Number: 20101299 Start Date*: 2012-06-12
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 299)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001626-26 Sponsor Protocol Number: OMT28-C0201 Start Date*: 2019-01-23
    Sponsor Name:OMEICOS Therapeutics GmbH
    Full Title: A Placebo-controlled, double-blind, Randomized, dose finding phase II study on OMT-28 in MaIntenance of Sinus rhythm after Electrical cardioversion in patients with persistent Atrial Fibrillation (...
    Medical condition: Persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004845-42 Sponsor Protocol Number: 20110165 Start Date*: 2012-05-30
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006787-11 Sponsor Protocol Number: 0819D1522 Start Date*: 2009-01-15
    Sponsor Name:Shionogi & Co., Ltd.
    Full Title: A randomized, double blind, placebo-controlled, 2-period cross over study to evaluate effects of S-555739 on prostaglandin D2 (PGD2) induced nasal airway resistance in healthy adult volunteers
    Medical condition: Allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006013-24 Sponsor Protocol Number: OC000459/012/08 Start Date*: 2009-03-25
    Sponsor Name:Oxagen Ltd.
    Full Title: Dose Finding Study in Patients with Mild to Moderate Persistent Asthma: A Parallel Group, Randomised, Placebo Controlled, Double Blind Assessment of Oral OC000459 Dosed at Three Dose Schedules for ...
    Medical condition: Mild to moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-002730-16 Sponsor Protocol Number: GLS27-005 Start Date*: 2021-10-25
    Sponsor Name:GeneOne Life Science Inc.
    Full Title: Safety, Tolerability, Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis caused by SARS-CoV-2 Infection
    Medical condition: Patients with SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002620-17 Sponsor Protocol Number: B7461001 Start Date*: 2014-03-21
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: Phase 1/2 study of PF-06463922 (an ALK/ROS1 tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer harboring specific molecular alterations.
    Medical condition: Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) or ROS oncogene 1 (ROS1)-positive (ROS1+) advanced non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003307-16 Sponsor Protocol Number: OMT28-C0203 Start Date*: 2023-04-18
    Sponsor Name:OMEICOS Therapeutics GmbH
    Full Title: A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD patients with myopathy and/or cardiomyopathy and inflammation (PMD-OPTION)
    Medical condition: Primary Mitochondrial Disease (PMD)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10010331 - Congenital, familial and genetic disorders 10052641 Mitochondrial DNA mutation PT
    22.0 10010331 - Congenital, familial and genetic disorders 10052641 Mitochondrial DNA mutation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003533-24 Sponsor Protocol Number: CA182033 Start Date*: 2009-04-29
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study) Pharmacogeneti...
    Medical condition: advanced hepatocellular carcinoma /////////// Carcinoma Hepatocelular avanzado
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003108-27 Sponsor Protocol Number: AX8-001 Start Date*: 2017-10-19
    Sponsor Name:Axalbion SA
    Full Title: A PILOT STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF AX-8 FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH.
    Medical condition: Refractory Chronic Cough (RCC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016024 10066656 Chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000358-65 Sponsor Protocol Number: A00394 Start Date*: 2005-11-21
    Sponsor Name:UCB Pharma S.A.
    Full Title: A multicentre, double-blind, two parallel groups, randomized trial over four weeks of treatment to compare the clinical efficacy and safety of Levocetirizine 5 mg oral capsules once daily in the mo...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    8.0 10009159 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006788-35 Sponsor Protocol Number: 0818D1521 Start Date*: 2009-01-14
    Sponsor Name:Shionogi & Co., Ltd.
    Full Title: A randomised, double-blind, placebo-controlled, 2-period crossover study to evaluate effects of multiple oral doses of S-555739 on nasal allergen challenge in subjects with intermittent grass polle...
    Medical condition: Allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001973-66 Sponsor Protocol Number: ML42243 Start Date*: 2020-07-16
    Sponsor Name:ROCHE SPA
    Full Title: A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) IN COMBINATION WITH BEVACIZUMAB TO INVESTIGATE SAFETY AND EFFICACY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA NOT...
    Medical condition: Unresectable hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004857-86 Sponsor Protocol Number: CTP_CAP001 Start Date*: 2007-01-19
    Sponsor Name:Caprion Pharmaceuticals Inc.
    Full Title: A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidne...
    Medical condition: metastatic kidney cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10023405 Kidney cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-006062-36 Sponsor Protocol Number: NW-3509/008A/II/2020 Start Date*: 2021-06-30
    Sponsor Name:Newron Pharmaceuticals S.p.A.
    Full Title: A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 M...
    Medical condition: Chronic schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) CZ (Completed) ES (Ongoing) RO (Ongoing) HU (Completed) PL (Completed) EE (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005086-12 Sponsor Protocol Number: GAM-27 Start Date*: 2013-07-05
    Sponsor Name:Octapharma AG
    Full Title: Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis.
    Medical condition: relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) HU (Completed) DE (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005084-34 Sponsor Protocol Number: CA182034 Start Date*: 2009-02-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed...
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019829 Hepatocellular carcinoma recurrent LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) SE (Completed) FR (Completed) GR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-009318-41 Sponsor Protocol Number: A4091017 Start Date*: 2009-08-07
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
    Medical condition: Osteoarthritis of the knee or hip
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020108 Hips osteoarthritis LLT
    9.1 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) FR (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:21:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA